GlassScriptPhysician profile
Anwar Dudekula
NPI 1922145200
$7,617.89
in general payments reported to CMS, 2019-2025
32 companies · $1,884 in 2025
The $1,884 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,083 · 2020: $133 · 2021: $140 · 2022: $913 · 2023: $1,217 · 2024: $2,249 · 2025: $1,884.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,810 · Travel and Lodging: $2,539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,810.19 |
| Travel and Lodging | $2,539.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,049.85 | 2019-2025 | Exalt Model D, Spyglass, Overstitch Endoscopic Suturing System |
| Olympus Corporation of The Americas | $1,244.91 | 2019-2023 | Visiglide, Disposable Distal Attachment |
| Abbvie INC. | $967.07 | 2019-2025 | Viberzi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $291.08 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $252.45 | 2019-2025 | Xifaxan |
| Genzyme Corporation | $223.99 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $164.61 | 2022-2023 | Rebyota |
| Medtronic, INC. | $148.30 | 2021-2022 | |
| Madrigal Pharmaceuticals | $135.45 | 2024-2025 | Rezdiffra, Resmetirom |
| E.R. Squibb & Sons, L.L.C. | $130.60 | 2024 | Zeposia |
| Celgene Corporation | $114.89 | 2022-2024 | Zeposia |
| Pfizer INC. | $113.94 | 2021-2024 | |
| Gilead Sciences, INC. | $111.65 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $108.14 | 2020 | |
| Daiichi Sankyo INC. | $82.95 | 2022-2024 | Injectafer |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $61.95 | 2022-2023 | Sucraid |
| Intercept Pharmaceuticals, INC. | $49.06 | 2023-2025 | Ocaliva |
| Ardelyx, INC. | $45.91 | 2022-2025 | Ibsrela |
| Amgen INC. | $42.30 | 2022-2023 | Amjevita, Avsola |
| Alnylam Pharmaceuticals INC. | $41.34 | 2023-2025 | Givlaari |
| Merck Sharp & Dohme LLC | $32.09 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $30.20 | 2025 | Iqirvo |
| Celltrion USA INC. | $29.47 | 2025 | Vegzelma |
| Cook Medical LLC | $20.94 | 2023 | Echotip |
| Phathom Pharmaceuticals, INC. | $19.04 | 2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $18.46 | 2024 | |
| Blueprint Medicines Corporation | $17.19 | 2024 | Ayvakit |
| Regeneron Healthcare Solutions, INC. | $16.17 | 2022 | |
| Enterra Medical, INC. | $15.71 | 2023 | |
| Intra-Sana Laboratories | $15.16 | 2023 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Janssen Biotech, INC. | $12.15 | 2020 | |
| Olympus America INC. | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anwar Dudekula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.